Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2007-06-26
2007-06-26
Weber, Jon (Department: 1657)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C514S509000, C514S562000, C514S676000
Reexamination Certificate
active
10415136
ABSTRACT:
The present invention provides methods of treating or preventing vascular diseases caused by nitric oxide (NO) insufficiency. The methods encompass administering a composition comprising an antioxidant, a compound to treat cardiovascular diseases, a nitrosated compound, a compound that donates, transfers or relases NO, or is a NO synthase substrate, or endogenously stimulates NO synthesis, or stimulates levels of endothelium derived relaxing factor. In the said composition, a hydralazine compound may be an antioxidant, isosorbide mono-or dinitrate may be the compound to donate, transfer, release, or stimulate endogenous NO synthesis. The isorsorbide may also elevate endogenous levels of endotherlium-derived relaxing factor, or be a NO synthase substrate and angiotensin enzyme inhibitor may be nitrosated compound. Disclosed in the invention is also a method to treat, or prevent Renaud's syndrome by administering a therapeutically effective amount of an antioxidant, a NO donor, a nitrosated compound and novel sustained-release formulations (e.g. a transdermal patch).
REFERENCES:
patent: 4293565 (1981-10-01), Cordes et al.
patent: 4584315 (1986-04-01), Marshall
patent: 4868179 (1989-09-01), Cohn
patent: 5627191 (1997-05-01), Birch et al.
patent: 5645839 (1997-07-01), Chobanian et al.
patent: 5760069 (1998-06-01), Lukas-Laskey et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5902821 (1999-05-01), Lukas-Laskey et al.
patent: 5968983 (1999-10-01), Kaesemeyer
patent: 5973011 (1999-10-01), Noack et al.
patent: 6103769 (2000-08-01), Kelm
patent: 6117872 (2000-09-01), Maxwell et al.
patent: 6319515 (2001-11-01), Hidaka et al.
patent: 6458797 (2002-10-01), Adams et al.
patent: 2004/0063719 (2004-04-01), Adams et al.
patent: 0327263 (1989-08-01), None
patent: 0 968 713 (1998-05-01), None
patent: 09059152 (1997-03-01), None
patent: WO 95/26725 (1995-10-01), None
patent: WO 98/21193 (1998-05-01), None
patent: WO 99/00361 (1999-01-01), None
patent: WO 99/66921 (1999-12-01), None
patent: WO 99/67231 (1999-12-01), None
patent: WO 01/35961 (2001-05-01), None
Dupuis, Cardiovascular Drugs and Therapy, 8(3):501-507 (1994).
Cohn et al, The New England Journal of Medicine, 325(5):303-310 (1991).
Cohn et al, The New England Journal of Medicine, 314(24):1547-1552 (1986).
Carson et al, Circulation, Supplement I, 92(8):I31-I32, Abstract No. 0145 (1995).
Francis et al, Circulation, Supplement VI, 87(6):VI40-VI48 (1993).
Pierpont et al, Chest, 73(1):8-13 (1978).
Massie et al, The American Journal of Cardiology, 40:794-801 (1977).
Kaplan et al, Annals of Internal Medicine, 84:639-645 (1976).
Bauer et al, Circulation, 84(1):35-39 (1991).
The SOLVD Investigators, The New England Journal of Medicine, 327(10):685-691 (1992).
Ziesche et al, Circulation, 87(6):VI56-VI64 (1993).
Rector et al, Circulation, 87(6):VI71-VI77 (1993).
Carson et al, Journal of Cardiac Failure, 5(3):178-187 (Sep. 10, 1999).
Dries et al, The New England Journal of Medicine, 340(8):609-616 (Feb. 25, 1999).
Freedman et al, Drugs, 54(Supp. 3):41-50 (1997).
Sherman et al, Cardiologia, 42(2):177-187 (1997).
Biegelson et al, Coronary Artery Disease, 10-241-256 (1999).
Rudd et al, Am. J. Physiol., 277(46):H723-H739 (1999).
Hammerman et al, Am. J. Physiol., 277(46):H1579-H1592 (1999).
Loscalzo et al, Transactions of the American and Climatological Ass., 111:158-163 (2000).
Johnson, Clinical Pharmacy, vol. 5, pp. 536 and 541 (1986).
Turner et al, The American Journal of Cardiology, 47:910-916 (1981).
Massie et al, Circulation, 63(3):658-664 (1981).
Nelson et al, Journal of Cardiovascular Pharmacology, 5(4):574-579 (1983).
Leier et al, Circulation, 63(1):102-109 (1981).
Wilson et al, The American Journal of Medicine, 71:627-633 (1981).
Biddle et al, J. Clin. Pharmacol., 21:343-350 (1981).
Margorien et al, Clinical Research, 27(4):A617 (1979), incomplete.
Turner et al, Clinical Research, 29(2):246A (1981), abstract only.
Hibiya et al, Japanese Circulation Journal, 45:966 (Abstract No. 338) (1981), abstract only.
Franciosa et al, Circulation, 59(6):1085-1091 (1979).
Lanas et al, Rev. Med. Chile, 107:926-930 (1979), abstract only.
Usdin et al, Coeur, 10(1):119-128 (1979), article in french only abstract considered.
Jun. 21, 2004. Supplementary Partial European Search Report for EP 00 97 6651.0.
Franciosa, Joseph A., “African-American Heart Failure Trial (A-HeFT): Rationale, Design, and Methodology,” Journal of Cardiac Failure, vol. 8, No. 3, 2002, pp. 128-135.
Yancy, Clyde W., et al., “Race and the Response to Adrenergic Blockage with Carvedilol in Patients with Chronic Heart Failure,” N. Engl. J. Med., vol. 344, No. 18, May 3, 2001, pp. 1358-1365.
Yancy, Clyde W., “Heart Failure in African Americans: A Cardiovascular Enigma,” Journal of Cardiac Failure, vol. 6, No. 3, 2000, pp. 183-186.
Exner, Derek V., et al., “Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction,” N. Engl. J. Med., vol. 344, No. 18, May 3, 2001, pp. 1351-1357.
Packer, Milton, et al., “Effect of Carvedilol on Survival in Severe Chronic Heart Failure,” N. Engl. J. Med., vol. 344, No. 22, May 31, 2001, pp. 1651-1658.
“A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure,” N. Engl. J. Med., vol. 344, No. 22, May 31, 2001, pp. 1659-1667.
Braunwald, Eugene, “Expanding Indications for Beta-Blockers in Heart Failure,” N. Engl. J. Med., vol. 344, No. 22, May 31, 2001, pp. 1711-1712.
Schwartz, Robert S., “Racial Profiling in Medical Research,” N. Engl. J. Med., vol. 344, No. 18, May 3, 2001, pp. 1392-1393.
Levine, T. Barry, “Paradoxical Hypertension after Reversal of Heart Failure in Patients Treated with Intensive Vasodilator Therapy,” American Journal of Hypertension, Ltd., 1998; 11:1041-1047.
ABSTRACTS—Heart Failure 179A, JACC, Feb. 1999.
Kahn, Jonathan, “How a Drug Becomes “Ethnic”: Law, Commerce, and the Production of Racial Categories in Medicine,” Yale Journal of Heath Policy, Law, and Ethics IV:1 (2004), pp. 1-46.
Parker, John D., et al., “The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin,” The Journal of Pharmacology and Experimental Therapeutics, vol. 280, No. 2, pp. 866-875.
Kalinowski, Leszek, et al., “Race-Specific Differences in Endothelial Function—Predisposition of African Americans to Vascular Diseases,” Circulation, Jun. 1, 2004, pp. 2511-2517.
Tucker, A. T. et al. Nov. 13, 1999, “Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial”, lancet vol. 354, #13, pp. 1670-1675.
Apr. 05, 2005. Supplementary European Search Report from European Patent Application No. 01932915.0.
Burnier et al, Hypertension, 22(3):339-347 (Sep. 1993), recieved May 30, 2006.
von Lutterotti et al, American Journal of Hypertension, 4(4 Part 2):346S-349S (1991), recd May 30, 2006.
Massie et al, Br. Heart J., 45:376-384 (1981), recd. May 30, 2006.
Lanas et al, Rev. Med. Chile, 107:926-930 (1979).
Usdin et al, Coeur, 10(1):119-128 (1979).
Parker, John D., et al., “The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin,” The Journal of Pharmacology and Experimental Therapeutics, vol. 280, No. 2, pp. 866-875, 1997.
Loberg Michael D.
Loscalzo Joseph
Vita Joseph A.
Worcel Manuel
NitroMed Inc.
Srivastava Kailash C.
Weber Jon
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Methods of treating vascular diseases characterized by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating vascular diseases characterized by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating vascular diseases characterized by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855428